Eli Lilly shares pulled back roughly 5% from early July all-time highs near $1,249, closing at $1,148.84 on July 31, as investors position ahead of the August 5 Q2 2026 earnings report. The core GLP-1 franchise — Mounjaro and Zepbound — generated $12.82 billion in combined Q1 revenue, about 65% of total sales, and remains the central driver of the investment thesis.

Revenue exceeded expectations: Merck posted second-quarter 2026 sales of $16.6 billion, up 5% year over year and ahead of the $16.41 billion consensus estimate. Non-GAAP EPS beat convincingly: The company reported an adjusted loss of $0.13 per share, significantly better than the $0.27 loss Wall Street had forecast.

Revenue beat: GSK posted second-quarter turnover of £8.41 billion, exceeding the analyst consensus of £8.24 billion and rising 5% at constant exchange rates (CER). Profit outperformance: Core operating profit reached £2.80 billion, ahead of the £2.68 billion consensus, while core earnings per share (EPS) of 50.5 pence comfortably beat the 47.1 pence forecast.

Core EPS beat consensus handsomely: Q2 2026 core earnings per share (EPS) reached $2.63, up 21% year-over-year and well above the company-compiled consensus of $2.49. Revenue landed in line with expectations: Total revenue of $15.38 billion rose 6% from a year ago and matched the $15.39 billion consensus forecast.

Novartis reported Q2 2026 net sales of $14.4 billion, up 3% year-over-year in USD terms. Core earnings per share came in at $2.41, slightly below the prior year but ahead of analyst consensus estimates around $2.16–$2.17.

JNJ delivered strong Q2 2026 results with $25.3 billion in sales and raised full-year guidance, supporting steady performance in a diversified healthcare model. MRNA trades at approximately $68 with significant year-to-date gains exceeding 130%, though it faces expected revenue declines ahead of its July 31 earnings report.

Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion, up 6.6% year over year on a reported basis. Adjusted earnings per share reached $2.90, exceeding the consensus estimate of $2.85.

Analysts expect Q2 2026 adjusted EPS of approximately $2.85, up from $2.70 in Q1 2026. Consensus revenue estimate stands near $25.18 billion, reflecting modest year-over-year growth.

Johnson & Johnson shares surged approximately 13.5% over the past 30 days, climbing from $232.16 on June 8 to $263.40 on July 8, 2026, hitting a new 52-week high of $269.43 during the period. A Guggenheim upgrade to $270 with a "Top Pick" designation in large-cap biopharma triggered sharp buying momentum on June 26, accelerating the rally into quarter-end.

Price target in focus: $1,400 represents a widely discussed analyst target and a logical next milestone for Eli Lilly and Company (LLY) , implying roughly 15% upside from recent levels near $1,215. Strongest bullish factors: An industry-leading portfolio of GLP-1 drugs, a historic $27 billion manufacturing expansion, and expanding insurance coverage are creating a powerful revenue flywheel.

Johnson & Johnson shares surged approximately 18% over the last 30 days, climbing from $222.89 on June 2 to $263.04 on July 2, 2026. A Guggenheim analyst upgrade with a $270 price target and a $1 billion Firefly Bio acquisition fueled strong investor optimism around the oncology pipeline.

Eli Lilly shares surged approximately 14.1% over the past 30 days, climbing from $1,064.15 on June 2 to $1,213.91 on July 2, 2026. The rally was fueled by a combination of robust quarterly earnings, raised full-year guidance, and accelerating demand for the company’s GLP-1 obesity and diabetes franchises.

Novo Nordisk (NVO) shares surged approximately 20% over the last 30 days, climbing from $42.00 to $50.43. The broader quarterly performance was even stronger, with the stock gaining roughly 38% since early April.

AbbVie shares surged approximately 17.6% over the past 30 days, climbing from $215.40 on May 27, 2026, to $253.35 at the June 26 close, hitting a new all-time high. The rally was fueled by the announced $10.9 billion acquisition of Apogee Therapeutics, strengthening AbbVie's immunology pipeline with an experimental eczema drug.

LLY shares surged +6.67% during regular market trading on June 26, climbing from a prior close of $1,127.69 to $1,202.86. The primary catalyst was the European Medicines Agency's CHMP issuing a positive opinion recommending approval of Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia across all lines of therapy in the EU.

Eli Lilly and Company (LLY) shares rose approximately 14.6% over the past 30 days, driven by sustained momentum in its obesity and diabetes franchises. Over the last quarter, the stock advanced roughly 14.3%, reflecting broader investor confidence in the company’s cardiometabolic pipeline and revenue growth trajectory.

GSK stock declined approximately -14% over the past 30 days, primarily due to a sharp post-Q1 earnings drop amid investor concerns over one-off boosts and general medicines weakness. Over the past quarter, the stock is down around -8%, reflecting volatility after earlier peaks from Q4 strength, offset by recent sector pressures and valuation reassessments.

Gilead Sciences reported Q1 2026 total revenues of $6.96 billion, up 4% year-over-year and beating consensus estimates of $6.91 billion. Non-GAAP diluted EPS came in at $2.03, surpassing expectations of $1.91 and up 12% from $1.81 in Q1 2025.

Analysts expect Q1 2026 revenue of $6.92 billion, up 3.4% from $6.67 billion in Q1 2025. Consensus EPS estimate stands at $1.91 per share, reflecting a 5.5% increase year-over-year based on non-GAAP figures from prior year.

Novo Nordisk is scheduled to report Q1 2026 results on May 6, 2026, before market open. Analysts expect EPS of $0.87, down about 5% year-over-year from Q1 2025's $0.92.